Idarrubicina Hikma

Idarubicin, the active ingredient in Idarrubicina Hikma, is an anthracycline antibiotic presented as a sterile powder for intravenous infusion for adult patients with hematologic cancers. It is used to treat acute myeloid leukemia and acute lymphoblastic leukemia by targeting rapidly dividing malignant cells.

GNH USA supplies Idarrubicina Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Idarubicin is an anthracycline chemotherapy employed primarily in hematologic malignancies.

Acute Myeloid Leukemia: induces remission in newly diagnosed or relapsed disease. Acute Lymphoblastic Leukemia: used in combination regimens for adult patients to achieve complete remission.

Idarubicin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Alopecia (hair loss) - Myelosuppression (decreased blood cell counts) - Mucositis (inflammation of the mouth lining) - Fatigue - Diarrhea

Serious or Rare Side Effects: - Cardiotoxicity (potential heart failure) - Severe neutropenia leading to infection - Hemorrhage or bleeding disorders - Secondary acute myeloid leukemia - Hypersensitivity or anaphylactic reactions - Hepatic toxicity (elevated liver enzymes).

When using Idarrubicina Hikma, clinicians should observe several safety measures.

Cardiac monitoring: perform baseline and periodic echocardiograms. Hematologic monitoring: regular complete blood counts to detect myelosuppression. Liver function monitoring: assess hepatic enzymes before and during therapy. Avoid use in patients with known hypersensitivity to anthracyclines. Use caution in renal impairment: adjust supportive care as needed. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Idarubicin can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent use of other anthracyclines (increased cardiotoxicity). - Co‑administration with trastuzumab or other HER2‑targeted agents (enhanced heart risk). - Strong CYP3A4 inhibitors that may raise idarubicin plasma levels.

Moderate Interactions (Monitor Closely): - Additional myelosuppressive drugs (potentiated bone‑marrow suppression). - Anticoagulants (increased bleeding risk). - Loop diuretics (may exacerbate electrolyte disturbances).